Valuation: Protalix BioTherapeutics, Inc.

Market Cap 19Cr 0 16Cr 15Cr 14Cr 26Cr 1.77TCr 27Cr 178.94Cr 70Cr 867.68Cr 70Cr 68Cr 3.01TCr P/E 2026 *
11.8x
P/E 2027 * 46x
Enterprise Value 19Cr 0 16Cr 15Cr 14Cr 26Cr 1.77TCr 27Cr 178.94Cr 70Cr 867.68Cr 70Cr 68Cr 3.01TCr EV / Sales 2026 *
2.37x
EV / Sales 2027 * 2.74x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2019
Director of Finance/CFO 58 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 82 01/11/2014
Director/Board Member 58 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 19Cr
+2.83%+3.33%+60.36%+174.15% 1,07000Cr
+3.19%+5.25%+72.15%+67.85% 62TCr
+1.75%+2.75%+37.80%+90.82% 45TCr
-0.43%+0.53%+31.00%+25.82% 33TCr
+2.13%+2.11%+40.91%+42.41% 29TCr
+1.33%+0.22%+29.97%+49.41% 28TCr
+1.97%+4.18%-25.71%-38.97% 22TCr
+1.39%+2.59%+26.81%+69.90% 20TCr
+3.78%+6.26%+20.10%+80.40% 16TCr
Average +1.78%+1.07%+32.60%+62.42% 40.27TCr
Weighted average by Cap. +2.19%+0.77%+44.21%+89.06%

Financials

2026 *2027 *
Net sales 7.83Cr 0 6.86Cr 6.32Cr 5.86Cr 11Cr 746.87Cr 11Cr 76Cr 29Cr 366.61Cr 29Cr 29Cr 1.27TCr 6.76Cr 0 5.92Cr 5.45Cr 5.06Cr 9.61Cr 644.48Cr 9.74Cr 65Cr 25Cr 316.35Cr 25Cr 25Cr 1.1TCr
Net income 1.57Cr 0 1.38Cr 1.27Cr 1.18Cr 2.24Cr 149.97Cr 2.27Cr 15Cr 5.91Cr 74Cr 5.9Cr 5.77Cr 255.24Cr 40.74L 0 35.68L 32.86L 30.5L 57.92L 39Cr 58.7L 3.93Cr 1.53Cr 19Cr 1.53Cr 1.5Cr 66Cr
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.300USD
Average target price
11.00USD
Spread / Average Target
+378.26%

Quarterly revenue - Rate of surprise